CMS makes ocular surface anesthesia more accessible

CMS has issued a product-specific code for Harrow’s new ocular surface anesthesia Iheezo, enabling a more efficient billing process for healthcare providers. 

Advertisement

Iheezo, a topical anesthetic approved by the FDA in Sept. 2022, is the first ocular anesthetic approved for use in 14 years, according to a Feb. 2 press release. 

Iheezo does not require patients to receive any supplemental anesthesia to undergo surgical procedures. 

By receiving a product-specific CMS code, ophthalmologists, optometrists and retina specialists will be able to easily bill for Iheezo, creating greater accessibility for the product. 

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.